Developer docs
API playgroundTry for free, no card

Search company profiles

Related Sciences

Full company profile

uuid0009e63

Namestring
Related Sciences
Legal namestring
Related Sciences
Websiteurl
related.vc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Related Sciences (RS) is a data science-driven drug discovery venture studio founded in 2019 and headquartered in Denver, Colorado. The firm operates a proprietary AI/ML platform called Facets™, built on the RS Biomedical Atlas — a curated integration of 70+ public, private, and RS-proprietary biomedical datasets — to systematically rank approximately 250 million target-disease drug discovery opportunities across hundreds of proprietary risk-reward metrics. RS selects the top-ranking opportunities and bundles them into themed portfolios ("constellations") of 5–15 programs that are incubated inside dedicated portfolio companies. The first constellation was launched in July 2021 as Danger Bio, financed with $25.5M and staffed by 15 luminary scientific founders; it currently holds 15 preclinical programs (8 with valid chemical matter, 4 prioritized as lead franchises) targeting innate immunity pathways in cancer immunotherapy, autoimmunity, and inflammatory diseases. A second constellation has been announced but its therapeutic focus is not yet disclosed.

The firm executes a hub-and-spoke R&D model, partnering with eight major service and technology providers — most notably Evotec (partnership extended through 2030 to include covalent inhibitor discovery), Charles River (Logica AI platform), OpenBench (structure-based ML), DyNAbind, and Adimab — to convert fixed lab and overhead costs into variable expenses, with company-stated R&D cost reductions of 40%+ and capex elimination of 40–60% relative to traditional biotech. RS's go-to-market targets pharmaceutical and biotechnology acquirers seeking preclinical assets, with revenue mechanics encompassing portfolio equity ownership, R&D milestone payments, royalties, and program acquisition exits. A decentralized team science model engages more than 100 global scientists and 8 senior advisors drawn from former CEOs and R&D heads at Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca. RS is privately held, does not disclose revenue, and operates with a lean core team in the 1–10 employee band supplemented by this distributed scientific network.

Short descriptiontext

Related Sciences is a Denver-based, AI-native drug discovery venture studio that uses its proprietary Facets™ platform to rank 250 million target-disease opportunities and build themed preclinical portfolios (constellations) for eventual pharma acquisition, starting with Danger Bio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, biotech venture creation, AI drug prioritization, pharmaceutical R&D services, decentralized biotech research
Industry1 code
PRIMARYBPACADAL
Life Sciences & Biotech (R&D/Clinical) Staffing
Business & Public Services/HR, Staffing & Recruitment Services/Professional & Technical Staffing (IT/Engineering/Healthcare/Finance)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech Drug Discovery
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Biotech Company Creation and Portfolio Investment
TypeLicensing Royalties
Description

Related Sciences builds and manages risk-optimized biotech companies (constellations/portfolios). The company centralizes and systematizes world-class capabilities to efficiently discover valuable new drugs and invests in unique portfolios of top-ranking programs. Revenue is generated through equity ownership in portfolio companies and eventual exits via acquisition or clinical progression.

related.vc
2R&D Partnerships and Milestones
TypeProfessional Services
Description

Partnerships with R&D service providers and pharmaceutical companies generate milestone payments, royalties, and equity stakes. RS works with 8 major R&D partners including Evotec, which provides access to global network of cutting-edge laboratories, multi-modality screening capabilities, and thousands of expert drug discovery scientists.

related.vc
3Drug Program Acquisition/Exit
TypeTransaction Fee
Description

Earlier exits at lower valuations but with significantly smaller risks of failure, timelines, and capital requirements can offer enhanced overall risk-adjusted expected returns. RS optimizes program selection, team design, and business development strategies to increase possibilities of early acquisition interest in completed preclinical drugs while retaining full optionality to progress into clinic.

related.vc
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Facets™
Description

Proprietary machine learning platform that ingests all activities in global biomedicine and systematically predicts the best new drug discovery opportunities for every disease on an unbiased, quantified, and explainable basis.

related.vc
+2 more records
Core offering1 text field

Related Sciences is a data science-driven drug foundry that uses its proprietary Facets™ AI/ML platform to systematically rank millions of target-disease drug discovery opportunities and build risk-optimized portfolios ("constellations") of drug programs. The company operates a decentralized team science model with 100+ global scientists and partners with CROs such as Evotec, Charles River, and OpenBench to advance preclinical programs, creating portfolio companies such as Danger Bio for eventual acquisition, partnership, or licensing by pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 40%+ reduction in R&D cost structures
+5 more records
Product overview1 text field

Related Sciences operates as a data science-driven drug discovery firm combining proprietary AI/ML technology with a decentralized R&D model. The core offering is the Facets™ Prioritization Engine, a machine learning platform that ingests 70+ biomedical datasets and systematically ranks millions of target-disease opportunities to identify the best drug discovery prospects. RS builds portfolio companies ('constellations') including Danger Bio (Constellation I focused on innate immunity), each comprising 5-15 top-ranking programs in ascendant therapeutic areas. The company utilizes a hub-and-spoke R&D model partnering with global service providers including Evotec, Charles River, and OpenBench. RS also develops and open-sources select bioinformatics tools (nxontology, ensembl-genes, articat, gce-github-runner) available on GitHub. RS currently has 15+ active preclinical drug programs across immunology and inflammatory biology.

Product and service5 records
1Facets™ Prioritization Engine
CategoryAI/ML Drug Discovery Platform
Description

Proprietary machine learning platform that ingests 70+ biomedical datasets and systematically ranks ~250 million target-disease drug discovery opportunities across hundreds of quantitative risk-reward metrics, identifying top programs with 4-5x higher likelihood of advancing beyond phase 2. Used to select and prioritize drug programs across RS portfolios.

2Danger Bio
CategoryPortfolio Biotech Company
Description

Flagship RS portfolio company focused on drugging the immune system's evolutionarily critical 'danger prevention' systems to treat root driver biology of immune-mediated diseases. Includes 15 preclinical programs across immune oncology, autoimmune/inflammatory diseases, and systemic lupus erythematosus with 15 scientific founders and 100+ drug discovery specialists.

3RS Constellation I (Danger Bio)
CategoryThemed Drug Discovery Portfolio
Description

First themed portfolio (constellation) of 5-15 top-ranking drug discovery opportunities in ascendant areas of research, launched in 2021 with Danger Bio as the operating vehicle. Targets innate immunity 'alarm system' biology with optimal risk-reward characteristics and portfolio-level risk diversification.

4RS Constellation II
CategoryThemed Drug Discovery Portfolio
Description

Second RS constellation themed portfolio of top-ranking drug discovery opportunities, expanding the firm's evergreen pipeline of new medicines beyond Constellation I.

5R&D Partnership Programs
CategoryR&D Partnership Services
Description

Integrated R&D partnership programs with leading CROs and technology providers (Evotec, Charles River, OpenBench, DyNAbind, Adimab) that execute preclinical discovery across multiple modalities under risk-sharing business models with milestone, royalty, and equity components.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-14
Description

Charles River and Related Sciences entered a multi-program collaboration to apply Logica (AI-powered drug solution from Charles River and Valo Health) across several previously undrugged targets in the RS portfolio. Logica combines AI/ML-enabled in silico discovery, high-powered DNA-encoded libraries, and traditional screening techniques. The partnership operates under a risk-sharing business model.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-06
Description

OpenBench provides structure-based machine learning platform for success-driven small molecule discovery. The collaboration applies OpenBench's discovery approach to current and future targets prioritized by the RS Facets™ platform. OpenBench bears the cost of virtual screening, custom synthesis, and experimental confirmation, with RS paying only for hits and leads meeting activity and developability criteria.

Strategic tierFlagship/CoreTypeStrategic or Co-development PartnerAnnounced on2023-02-09
Description

Evotec is a key strategic partner providing integrated drug discovery services across the full R&D continuum. The partnership oversees a growing portfolio of more than 15 multi-modality drug discovery programs. The partnership was extended through 2030 to include Evotec's industry-leading capabilities in covalent inhibitor discovery, leveraging custom covalent libraries and novel screening approaches. Evotec is eligible to receive milestones, royalties, and a founding equity stake in all RS assets developed under the partnership.

4Danger Bio
Strategic tierFlagship/CoreTypeStrategic or Co-development PartnerAnnounced on2021-07-07
Description

Danger Bio is Related Sciences' flagship portfolio company focused on drugging the immune system's 'danger prevention' systems to treat immune-mediated diseases. Launched in July 2021 with $25.5M initial financing, Danger Bio has 15 scientific founders from top academic institutions and 100+ drug discovery specialists. The company targets cancer immunotherapy, autoimmunity, and inflammatory diseases through modulation of innate immunity pathways.

related.vc
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest biotech venture creation firm (where RS co-founder Milwid previously worked). Spawns and funds multiple platform companies across therapeutic areas—structurally analogous to RS's constellation model but at vastly greater scale, with a deeper clinical pipeline track record.

TypeDirect peer
Description

Computational drug discovery platform combining physics-based simulation, ML, and a SaaS offering used by pharma. Directly comparable to RS on the AI/computation-for-drug-discovery axis, with a publicly disclosed revenue base and partnered programs.

TypeEmerging player
Description

AI-driven drug discovery company combining deep learning, physics, and chemistry to discover novel therapeutics. Emerging-stage peer with overlapping technology stack to RS's ML-driven prioritization approach, though smaller in headcount and pipeline scale.

TypeDirect peer
Description

AI-first drug discovery company launched in 2024 with $1B+ from Foresite Labs and ARCH Venture Partners, focused on end-to-end AI-enabled therapeutic discovery. Most direct recent competitor to RS on AI-driven drug creation model and platform architecture.

5Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company spun out of DeepMind, building computational models to predict drug behavior. Most well-capitalized peer pursuing target-disease prioritization with proprietary ML models, comparable to RS's Facets™ thesis.

TypeBroad incumbent
Description

Clinical-stage biotech using a portfolio approach of multiple genetically validated programs. Comparable to RS on the multi-program risk-diversified model and on centralized resource allocation across therapeutic-area programs.

TypeBroad incumbent
Description

Publicly traded biotech holding company that creates and incubates subsidiary biotech companies focused on specific therapeutic assets. Closest publicly traded analog to RS's multi-portfolio venture creation model with similar BD-driven exit strategy.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Targets a similar workflow of data-driven target identification and partnered pharma programs, with comparable funding-stage profile.

TypeDirect peer
Description

Publicly traded AI/ML-driven drug discovery company combining high-throughput biology, proprietary datasets, and ML models to identify novel therapeutics. Closest publicly comparable analog to RS's Facets™ platform approach, though at much larger scale and with clinical-stage assets.

TypeDirect peer
Description

AI-driven small molecule drug design company using structure-based ML to discover novel compounds. Comparable to RS on the AI target/opportunity prioritization layer and on multi-program pharma partnership model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Related Sciences

Biotech Drug Discoveryrelated.vc

Related Sciences is a Denver-based, AI-native drug discovery venture studio that uses its proprietary Facets™ platform to rank 250 million target-disease opportunities and build themed preclinical portfolios (constellations) for eventual pharma acquisition, starting with Danger Bio.

What Related Sciences does

Related Sciences (RS) is a data science-driven drug discovery venture studio founded in 2019 and headquartered in Denver, Colorado. The firm operates a proprietary AI/ML platform called Facets™, built on the RS Biomedical Atlas — a curated integration of 70+ public, private, and RS-proprietary biomedical datasets — to systematically rank approximately 250 million target-disease drug discovery opportunities across hundreds of proprietary risk-reward metrics. RS selects the top-ranking opportunities and bundles them into themed portfolios ("constellations") of 5–15 programs that are incubated inside dedicated portfolio companies. The first constellation was launched in July 2021 as Danger Bio, financed with $25.5M and staffed by 15 luminary scientific founders; it currently holds 15 preclinical programs (8 with valid chemical matter, 4 prioritized as lead franchises) targeting innate immunity pathways in cancer immunotherapy, autoimmunity, and inflammatory diseases. A second constellation has been announced but its therapeutic focus is not yet disclosed.

The firm executes a hub-and-spoke R&D model, partnering with eight major service and technology providers — most notably Evotec (partnership extended through 2030 to include covalent inhibitor discovery), Charles River (Logica AI platform), OpenBench (structure-based ML), DyNAbind, and Adimab — to convert fixed lab and overhead costs into variable expenses, with company-stated R&D cost reductions of 40%+ and capex elimination of 40–60% relative to traditional biotech. RS's go-to-market targets pharmaceutical and biotechnology acquirers seeking preclinical assets, with revenue mechanics encompassing portfolio equity ownership, R&D milestone payments, royalties, and program acquisition exits. A decentralized team science model engages more than 100 global scientists and 8 senior advisors drawn from former CEOs and R&D heads at Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca. RS is privately held, does not disclose revenue, and operates with a lean core team in the 1–10 employee band supplemented by this distributed scientific network.

Related Sciences firmographics

Firmographics
Name
Related Sciences
Legal name
Related Sciences
Website
https://related.vc
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Related Sciences is a Denver-based, AI-native drug discovery venture studio that uses its proprietary Facets™ platform to rank 250 million target-disease opportunities and build themed preclinical portfolios (constellations) for eventual pharma acquisition, starting with Danger Bio.
Ownership category
akta.pro rank

Related Sciences industry classification

Industry
Product category
Biotech Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPACADAL
Life Sciences & Biotech (R&D/Clinical) Staffing
Business & Public Services/HR, Staffing & Recruitment Services/Professional & Technical Staffing (IT/Engineering/Healthcare/Finance)

Keywords

  • Drug discovery platform
  • Biotech venture creation
  • AI drug prioritization
  • Pharmaceutical R&D services
  • Decentralized biotech research

Where Related Sciences is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Related Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biotech Company Creation and Portfolio Investment: Related Sciences builds and manages risk-optimized biotech companies (constellations/portfolios). The company centralizes and systematizes world-class capabilities to efficiently discover valuable new drugs and invests in unique portfolios of top-ranking programs. Revenue is generated through equity ownership in portfolio companies and eventual exits via acquisition or clinical progression.
  2. R&D Partnerships and Milestones: Partnerships with R&D service providers and pharmaceutical companies generate milestone payments, royalties, and equity stakes. RS works with 8 major R&D partners including Evotec, which provides access to global network of cutting-edge laboratories, multi-modality screening capabilities, and thousands of expert drug discovery scientists.
  3. Drug Program Acquisition/Exit: Earlier exits at lower valuations but with significantly smaller risks of failure, timelines, and capital requirements can offer enhanced overall risk-adjusted expected returns. RS optimizes program selection, team design, and business development strategies to increase possibilities of early acquisition interest in completed preclinical drugs while retaining full optionality to progress into clinic.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Related Sciences product offering

Product offering

Core offering

Related Sciences is a data science-driven drug foundry that uses its proprietary Facets™ AI/ML platform to systematically rank millions of target-disease drug discovery opportunities and build risk-optimized portfolios ("constellations") of drug programs. The company operates a decentralized team science model with 100+ global scientists and partners with CROs such as Evotec, Charles River, and OpenBench to advance preclinical programs, creating portfolio companies such as Danger Bio for eventual acquisition, partnership, or licensing by pharmaceutical companies.

Product overview

Related Sciences operates as a data science-driven drug discovery firm combining proprietary AI/ML technology with a decentralized R&D model. The core offering is the Facets™ Prioritization Engine, a machine learning platform that ingests 70+ biomedical datasets and systematically ranks millions of target-disease opportunities to identify the best drug discovery prospects. RS builds portfolio companies ('constellations') including Danger Bio (Constellation I focused on innate immunity), each comprising 5-15 top-ranking programs in ascendant therapeutic areas. The company utilizes a hub-and-spoke R&D model partnering with global service providers including Evotec, Charles River, and OpenBench. RS also develops and open-sources select bioinformatics tools (nxontology, ensembl-genes, articat, gce-github-runner) available on GitHub. RS currently has 15+ active preclinical drug programs across immunology and inflammatory biology.

Differentiator

Problem solved

Functional benefit

Brands

  • Facets™: Proprietary machine learning platform that ingests all activities in global biomedicine and systematically predicts the best new drug discovery opportunities for every disease on an unbiased, quantified, and explainable basis.
  • RS Biomedical Atlas
  • Danger Bio

Products and services

  • Facets™ Prioritization Engine Proprietary machine learning platform that ingests 70+ biomedical datasets and systematically ranks ~250 million target-disease drug discovery opportunities across hundreds of quantitative risk-reward metrics, identifying top programs with 4-5x higher likelihood of advancing beyond phase 2. Used to select and prioritize drug programs across RS portfolios.
  • Danger Bio Flagship RS portfolio company focused on drugging the immune system's evolutionarily critical 'danger prevention' systems to treat root driver biology of immune-mediated diseases. Includes 15 preclinical programs across immune oncology, autoimmune/inflammatory diseases, and systemic lupus erythematosus with 15 scientific founders and 100+ drug discovery specialists.
  • RS Constellation I (Danger Bio) First themed portfolio (constellation) of 5-15 top-ranking drug discovery opportunities in ascendant areas of research, launched in 2021 with Danger Bio as the operating vehicle. Targets innate immunity 'alarm system' biology with optimal risk-reward characteristics and portfolio-level risk diversification.
  • RS Constellation II Second RS constellation themed portfolio of top-ranking drug discovery opportunities, expanding the firm's evergreen pipeline of new medicines beyond Constellation I.
  • R&D Partnership Programs Integrated R&D partnership programs with leading CROs and technology providers (Evotec, Charles River, OpenBench, DyNAbind, Adimab) that execute preclinical discovery across multiple modalities under risk-sharing business models with milestone, royalty, and equity components.

Quantifiable outcome

  • 40%+ reduction in R&D cost structures
  • +5 more outcomes

Companies that use Related Sciences

Customer profile

Segments3 records

Ideal customer profiles2 records

Related Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Related Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship/core.

  • Charles River LaboratoriescoreStrategic or Co-development Partner · 14 September 2023Charles River and Related Sciences entered a multi-program collaboration to apply Logica (AI-powered drug solution from Charles River and Valo Health) across several previously undrugged targets in the RS portfolio. Logica combines AI/ML-enabled in silico discovery, high-powered DNA-encoded libraries, and traditional screening techniques. The partnership operates under a risk-sharing business model.
  • OpenBenchcoreTechnology or Integration · 6 June 2023OpenBench provides structure-based machine learning platform for success-driven small molecule discovery. The collaboration applies OpenBench's discovery approach to current and future targets prioritized by the RS Facets™ platform. OpenBench bears the cost of virtual screening, custom synthesis, and experimental confirmation, with RS paying only for hits and leads meeting activity and developability criteria.
  • Evotec SEflagship/coreStrategic or Co-development Partner · 9 February 2023Evotec is a key strategic partner providing integrated drug discovery services across the full R&D continuum. The partnership oversees a growing portfolio of more than 15 multi-modality drug discovery programs. The partnership was extended through 2030 to include Evotec's industry-leading capabilities in covalent inhibitor discovery, leveraging custom covalent libraries and novel screening approaches. Evotec is eligible to receive milestones, royalties, and a founding equity stake in all RS assets developed under the partnership.
  • Danger Bioflagship/coreStrategic or Co-development Partner · 7 July 2021Danger Bio is Related Sciences' flagship portfolio company focused on drugging the immune system's 'danger prevention' systems to treat immune-mediated diseases. Launched in July 2021 with $25.5M initial financing, Danger Bio has 15 scientific founders from top academic institutions and 100+ drug discovery specialists. The company targets cancer immunotherapy, autoimmunity, and inflammatory diseases through modulation of innate immunity pathways.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Related Sciences competitors and assessment

Company assessment

Broad incumbents

  • Flagship Pioneering: Largest biotech venture creation firm (where RS co-founder Milwid previously worked). Spawns and funds multiple platform companies across therapeutic areas—structurally analogous to RS's constellation model but at vastly greater scale, with a deeper clinical pipeline track record.
  • BridgeBio Pharma: Clinical-stage biotech using a portfolio approach of multiple genetically validated programs. Comparable to RS on the multi-program risk-diversified model and on centralized resource allocation across therapeutic-area programs.
  • Roivant Sciences: Publicly traded biotech holding company that creates and incubates subsidiary biotech companies focused on specific therapeutic assets. Closest publicly traded analog to RS's multi-portfolio venture creation model with similar BD-driven exit strategy.

Direct peers

  • Schrödinger, Inc. Computational drug discovery platform combining physics-based simulation, ML, and a SaaS offering used by pharma. Directly comparable to RS on the AI/computation-for-drug-discovery axis, with a publicly disclosed revenue base and partnered programs.
  • Xaira Therapeutics: AI-first drug discovery company launched in 2024 with $1B+ from Foresite Labs and ARCH Venture Partners, focused on end-to-end AI-enabled therapeutic discovery. Most direct recent competitor to RS on AI-driven drug creation model and platform architecture.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind, building computational models to predict drug behavior. Most well-capitalized peer pursuing target-disease prioritization with proprietary ML models, comparable to RS's Facets™ thesis.
  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Targets a similar workflow of data-driven target identification and partnered pharma programs, with comparable funding-stage profile.
  • Recursion Pharmaceuticals: Publicly traded AI/ML-driven drug discovery company combining high-throughput biology, proprietary datasets, and ML models to identify novel therapeutics. Closest publicly comparable analog to RS's Facets™ platform approach, though at much larger scale and with clinical-stage assets.
  • Atomwise: AI-driven small molecule drug design company using structure-based ML to discover novel compounds. Comparable to RS on the AI target/opportunity prioritization layer and on multi-program pharma partnership model.

Emerging players

  • Genesis Therapeutics: AI-driven drug discovery company combining deep learning, physics, and chemistry to discover novel therapeutics. Emerging-stage peer with overlapping technology stack to RS's ML-driven prioritization approach, though smaller in headcount and pipeline scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Related Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Related Sciences leadership team

Management profile

Number of profiles

Profiles7 records

Related Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Related Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Related Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Related Sciences

What does Related Sciences do?

Related Sciences is a data science-driven drug foundry that uses its proprietary Facets™ AI/ML platform to systematically rank millions of target-disease drug discovery opportunities and build risk-optimized portfolios ("constellations") of drug programs. The company operates a decentralized team science model with 100+ global scientists and partners with CROs such as Evotec, Charles River, and OpenBench to advance preclinical programs, creating portfolio companies such as Danger Bio for eventual acquisition, partnership, or licensing by pharmaceutical companies.

Is Related Sciences a public or private company?

Related Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Related Sciences founded?

Related Sciences was founded in 2019. It employs 1 to 10 people.

Where is Related Sciences based?

Related Sciences is headquartered in Denver, United States, in the North America region.

How does Related Sciences make money?

Three revenue lines are on record. Biotech Company Creation and Portfolio Investment is the primary driver. The others are R&D Partnerships and Milestones and drug Program Acquisition/Exit.

Who are Related Sciences's main competitors?

Broad incumbents on record are Flagship Pioneering, BridgeBio Pharma and Roivant Sciences. Direct peers are Schrödinger, Inc., Xaira Therapeutics, Isomorphic Labs, Insitro, Recursion Pharmaceuticals and Atomwise. Genesis Therapeutics is listed as an emerging player.

Does Related Sciences have an API?

No public API is recorded for Related Sciences.

What industry is Related Sciences in?

Related Sciences's product category is Biotech Drug Discovery. Its primary akta.pro industry code is BPACADAL, Life Sciences & Biotech (R&D/Clinical) Staffing. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRelated Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZenecaRelated Sciences announced the appointment of eight senior biopharma executives as senior advisors to support its growing portfolio of drug programs and data science capabilities. The firm utilizes a proprietary machine learning platform called Facets to systematically identify therapeutic opportunities and employs a decentralized R&D model involving over 100 scientists. This advisory group is intended to help advance an initial portfolio of 15 drug programs focused on immunology and inflammatory biology.PR NewswireOpenBench and Related Sciences Launch Success-Driven CollaborationOpenBench, Inc. announced a collaboration with Related Sciences to leverage OpenBench's structure-based machine learning platform for identifying novel small molecule chemical hits for RS's drug discovery targets. Under the agreement, OpenBench receives payment upon successful identification and experimental confirmation of hits meeting defined activity and developability criteria, while RS gains exclusive purchase rights to discovered leads and access to OpenBench's proprietary screening technology. Both companies expect the collaboration to combine OpenBench's success-driven early discovery model with Related Sciences' Facets™ machine learning platform for target prioritization and rapid prosecution of therapeutic opportunities.